Flerie Invest AB has increased its holding in Lipum AB (publ), whereby the limit for mandatory bidding has been exceeded
THIS PRESS RELEASE DOES NOT CONSTITUTE A PUBLIC TENDER OFFER OR OTHERWISE AN OFFER TO ACQUIRE SHARES
Flerie Invest AB, reg no. 556856-6615 (“Flerie”) has today acquired 859 shares in Lipum AB (publ) reg. no. 556813-5999 (“Lipum”). Flerie’s total holding in Lipum following the acquisition amounts to 2 981 553 shares, comprising 32,01 per cent of the total amount of shares and votes in the company.
According to the Swedish Securities Council’s statement AMN 2023:23, Flerie was granted an exemption from the obligation to make a mandatory bid that could arise as a result of Flerie subscribing its share in the rights issue that Lipum carried out in 2023. According to the exception, an obligation to make a mandatory bid arises if Flerie subsequently acquires additional shares and thereby increases its voting rights in Lipum.
Through today’s acquisition of additional shares in Lipum, an obligation to make a mandatory bid arises. Flerie intends to revert with information about a possible public takeover bid regarding the remaining shares in Lipum within four weeks.
For further information, please contact:
Thomas Eldered, Executive Chairman or Cecilia Scheele, CFO
Both can be contacted at contact@flerie.com +46 (0)76 131 0127
This information was submitted for publication on 1 March 2024 at 17:00 CET.
About Flerie
Flerie is an active long-term global biotech and pharma investor based in Stockholm and London managing a portfolio of over 30 investments in Europe, Israel and the US. Flerie’s evergreen investment strategy, operational expertise and network enables pioneering technologies in the drug development and services space to advance on their path to treating patients and commercialization. Flerie was founded in 2011 by Thomas Eldered, who also co-founded and built Recipharm to be one of the world’s top five pharmaceutical contract manufacturers. For more information, please visit www.flerie.com.